Login to Your Account



Stock Tanks 28%

AVI's DMD Drug Ups Dystrophin, Outcome Distresses Investors

By Karen Pihl-Carey
BioWorld Today Contributing Writer

Tuesday, April 3, 2012
AVI BioPharma Inc.'s Duchenne's muscular dystrophy (DMD) candidate eteplirsen hit its primary endpoint of significantly increasing dystrophin in a Phase IIb trial, although shares plummeted on Monday over the lack of clinical outcome improvement.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription